mProX™ Human CFTR Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Ion Channel Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
William
Verified Customer
John
Verified Customer
Any questions about our products? Please visit our frequently asked questions page.
Published Data
Fig.1 The CFTR-specific shRNA expression pGFP-V-RS vectors were used to transfect the human A2780 and SKOV3 epithelial ovarian cancer cell lines, and the stably transfected cells were then chosen.
Western blot analysis was used to quantify the CFTR protein (~170 kDa) in each puromycin-resistant cell, GFP-positive cell colonies, and negative control cells. As an internal control, β-actin (~43 kDa) was employed.
Ref: Xu, Jiao, et al. "High level of CFTR expression is associated with tumor aggression and knockdown of CFTR suppresses proliferation of ovarian cancer in vitro and in vivo." Oncology Reports 33.5 (2015): 2227-2234.
Pubmed: 25738998
DOI: 10.3892/or.2015.3829
Research Highlights
Although it is a member of the ATP binding cassette (ABC) transporter superfamily, the cystic fibrosis transmembrane conductance regulator (CFTR) serves as an anion channel that is essential for the passage of salt and water through epithelial cells.
Csanády, László, Paola Vergani, and David C. Gadsby. "Structure, gating, and regulation of the CFTR anion channel." Physiological reviews 99.1 (2019): 707-738.
Pubmed:
30516439
DOI:
10.1152/physrev.00007.2018
Modulator for CFTR theratyping is a new and quickly developing discipline that may be able to find uncommon CFTR variations that respond to medicines that are either approved or under development.
Clancy, John Paul, et al. "CFTR modulator theratyping: Current status, gaps and future directions." Journal of Cystic Fibrosis 18.1 (2019): 22-34.
Pubmed:
29934203
DOI:
10.1016/j.jcf.2018.05.004